share_log

艾力斯(688578.SH):伏美替尼新增适应症获得药物临床试验批准通知书

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): Received drug clinical trial approval letter for new indication of Venetoclax.

Gelonghui Finance ·  Jul 8 05:44

On July 8, Gelunhui reported that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) received the Notice of Approval for Drug Clinical Trial issued by the National Medical Products Administration for the clinical study of adding indications for Fovamteran Hydrochloride Tablets (Fovamteran). Fovamteran is a first-class molecular targeted drug independently developed by the company, which is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Fovamteran belongs to highly selective, irreversible third-generation EGFR-TKI with competitive advantages of 'strong brain penetration, excellent efficacy, good safety, and wide therapeutic window' for the treatment of EGFR-mutant non-small cell lung cancer. Both its second-line indication and first-line indication have been included in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug List (2023).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment